Sunhawk Vision Biotech (ROCO:7759) Total Equity: NT$471.80 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7759 Sunhawk Vision Biotech Inc ROCO:7759
12 GF Score
Price NT$31.40
! 1 Warning Sign
View Full Analysis

What is Sunhawk Vision Biotech Total Equity?

Sunhawk Vision Biotech ROCO:7759 +0.96% 12 Total Equity is NT$471.80 Mil as of Dec. 2025. GuruFocus rates ROCO:7759 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Sunhawk Vision Biotech's total equity for the quarter that ended in Dec. 2025 was NT$471.80 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sunhawk Vision Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for Sunhawk Vision Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunhawk Vision Biotech Total Equity Chart

Sunhawk Vision Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 107.52 142.34 309.56 296.18 471.80

Sunhawk Vision Biotech Semi-Annual Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only 309.56 290.48 296.18 548.16 471.80
ROCO:7759
12GF Score
Sunhawk Vision Biotech Inc ROCO:7759
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunhawk Vision Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sunhawk Vision Biotech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=498.806-27.007
=471.80

Sunhawk Vision Biotech's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=498.806-27.007
=471.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$471.80 Mil mean?
Sunhawk Vision Biotech (ROCO:7759) has a Total Equity of NT$471.80 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Sunhawk Vision Biotech and its competitors.
Is Sunhawk Vision Biotech's Total Equity too high?
Sunhawk Vision Biotech's current Total Equity is NT$471.80 Mil. Overall, Sunhawk Vision Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sunhawk Vision Biotech's Total Equity compare to VRTX and REGN?
Sunhawk Vision Biotech's Total Equity of NT$471.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sunhawk Vision Biotech and its competitors. Sunhawk Vision Biotech's current Total Equity is NT$471.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunhawk Vision Biotech stock overvalued right now?
Sunhawk Vision Biotech (ROCO:7759) has a current Total Equity of NT$471.80 Mil. The current Total Equity is NT$471.80 Mil. Sunhawk Vision Biotech's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sunhawk Vision Biotech (ROCO:7759), the current Total Equity is NT$471.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sunhawk Vision Biotech Business Description

Address No. 6 Siwei 3rd Road, 17th Floor, Room A1, Lingya District, Kaohsiung, TWN
Sunhawk Vision Biotech Inc is a biotechnology company. The company is focused on developing new solutions for eye health and vision care. The company specializes in research and development of cutting-edge technologies aimed at treating and preventing ocular diseases. Their product portfolio includes products and services for curing dry eyes, myopia, and corneal erosion.
12GF Score

Get the complete analysis for ROCO:7759

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.40
Price